322 related articles for article (PubMed ID: 33687951)
1. Hypothermia Effectively Treats Tumors with Temperature-Sensitive p53 Mutations.
Lu J; Chen L; Song Z; Das M; Chen J
Cancer Res; 2021 Jul; 81(14):3905-3915. PubMed ID: 33687951
[TBL] [Abstract][Full Text] [Related]
2. Hypothermia Is a Potential New Therapy for a Subset of Tumors with Mutant p53.
Hu W; Feng Z
Cancer Res; 2021 Jul; 81(14):3762-3763. PubMed ID: 34266914
[TBL] [Abstract][Full Text] [Related]
3. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
4. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Viotti J; Duplan E; Caillava C; Condat J; Goiran T; Giordano C; Marie Y; Idbaih A; Delattre JY; Honnorat J; Checler F; Alves da Costa C
Oncogene; 2014 Apr; 33(14):1764-75. PubMed ID: 23644658
[TBL] [Abstract][Full Text] [Related]
5. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library.
Shiraishi K; Kato S; Han SY; Liu W; Otsuka K; Sakayori M; Ishida T; Takeda M; Kanamaru R; Ohuchi N; Ishioka C
J Biol Chem; 2004 Jan; 279(1):348-55. PubMed ID: 14559903
[TBL] [Abstract][Full Text] [Related]
6. Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations.
Tang Y; Song H; Wang Z; Xiao S; Xiang X; Zhan H; Wu L; Wu J; Xing Y; Tan Y; Liang Y; Yan N; Li Y; Li J; Wu J; Zheng D; Jia Y; Chen Z; Li Y; Zhang Q; Zhang J; Zeng H; Tao W; Liu F; Wu Y; Lu M
Cell Rep; 2022 Apr; 39(2):110622. PubMed ID: 35417717
[TBL] [Abstract][Full Text] [Related]
7. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.
Song H; Wu J; Tang Y; Dai Y; Xiang X; Li Y; Wu L; Wu J; Liang Y; Xing Y; Yan N; Li Y; Wang Z; Xiao S; Li J; Zheng D; Chen X; Fang H; Ye C; Ma Y; Wu Y; Wu W; Li J; Zhang S; Lu M
Sci Transl Med; 2023 Apr; 15(690):eabn9155. PubMed ID: 37018419
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
9. Rescue of mutant p53 transcription function by ellipticine.
Peng Y; Li C; Chen L; Sebti S; Chen J
Oncogene; 2003 Jul; 22(29):4478-87. PubMed ID: 12881704
[TBL] [Abstract][Full Text] [Related]
10. Mild hypothermia reduces ischemic neuron death via altering the expression of p53 and bcl-2.
Zhang H; Xu G; Zhang J; Murong S; Mei Y; Tong E
Neurol Res; 2010 May; 32(4):384-9. PubMed ID: 20483005
[TBL] [Abstract][Full Text] [Related]
11. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
[TBL] [Abstract][Full Text] [Related]
12. Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations.
Koulgi S; Achalere A; Sonavane U; Joshi R
PLoS One; 2015; 10(11):e0143065. PubMed ID: 26579714
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
Kamada R; Nomura T; Anderson CW; Sakaguchi K
J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
[TBL] [Abstract][Full Text] [Related]
14. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains.
Ang HC; Joerger AC; Mayer S; Fersht AR
J Biol Chem; 2006 Aug; 281(31):21934-21941. PubMed ID: 16754663
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
16. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
17. A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis.
Subramanian M; Francis P; Bilke S; Li XL; Hara T; Lu X; Jones MF; Walker RL; Zhu Y; Pineda M; Lee C; Varanasi L; Yang Y; Martinez LA; Luo J; Ambs S; Sharma S; Wakefield LM; Meltzer PS; Lal A
Oncogene; 2015 Feb; 34(9):1094-104. PubMed ID: 24662829
[TBL] [Abstract][Full Text] [Related]
18. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
19. Regulation of mutant p53 temperature-sensitive DNA binding.
Friedlander P; Legros Y; Soussi T; Prives C
J Biol Chem; 1996 Oct; 271(41):25468-78. PubMed ID: 8810317
[TBL] [Abstract][Full Text] [Related]
20. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.
Tal P; Eizenberger S; Cohen E; Goldfinger N; Pietrokovski S; Oren M; Rotter V
Oncotarget; 2016 Mar; 7(11):11817-37. PubMed ID: 26943582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
